However, several other classes of biological DMARDs are now available, including the T-cell co-stimulatory modulator abatacept, the interleukin (IL)-6 pathway inhibitor tocilizumab, IL-1 inhibitors (including the IL-1 receptor antagonist anakinra and IL-1β inhibitor canakinumab), and the targeted B-cell depleting drug rituximab (not licensed for juvenile idiopathic arthritis). Here, IL1B is linked to juvenile idiopathic arthritis.